9 slides from Revvity's earnings presentation, Nov 3, 2026
Slide 1: Third Quarter 2026 Earnings
Third Quarter 2026 Earnings November 3, 2026
Slide 2: Safe Harbor
Safe Harbor This presentation contains "forward -looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financia
Slide 3: Key Takeaways
Key Takeaways Innovation Market Performance Improving Pharma/Biotech 3Q financial performance end market conditions above expectations Launched 3 -plex solution for early detection of T1D Volume and operational AI-related demand efficiency drove meaningful Announced acquisition of continuing to buil
Slide 4: 3Q26 Pro Forma Revenue Highlights
3Q26 Pro Forma* Revenue Highlights Segments Geographic Product Mix Diagnostics Life Sciences AMERICAS APAC EU Recurring Non -recurring -LSD -LSD +MSD $0.7B +HSD +DD $0.7B +HSD $0.7B +DD *Pro Forma excludes the impact of the China Immunodiagnostics business which the Company has agreed to divest 4
Slide 5: 3Q26 Financial Results
3Q26 Financial Results PRO FORMA REVENUE PRO FORMA ADJ. OP. MARGIN PRO FORMA ADJ. EPS FREE CASH FLOW $710M 29.4% $1.37 $152M +7% y/y +340bps y/y +21% y/y $451M YTD Organic: Adj. Gross Margin: Adj. Tax Rate: YTD FCF % Adj. NI: +7% | M&A: +1% | FX: -1% 62.4% | +280bps y/y 18.2% 105% Adj. Net Interest
Slide 6: Life Sciences
Life Sciences LIFE SCIENCES SOLUTIONS SOFTWARE PRO FORMA REVENUE ADJUSTED OP. MARGINS +DD +9% Organic Growth 31.5% Total: +11% | M&A: +2% | FX: 0 % +200bps y/y $380M 3Q26 pro forma • +LDD Pharma/Biotech & +MSD Academic/Gov’t revenue • +HSD Life Sciences Solutions, with both reagents and instruments
Slide 7: Diagnostics
Diagnostics IMMUNODIAGNOSTICS REPRODUCTIVE PRO FORMA REVENUE ADJUSTED OP. MARGINS HEALTH +5% Organic Growth 29.9% Total: +4% | M&A: 0% | FX: -1% +480bps y/y +LSD $330M • +HSD ImmunoDx with strength in the Americas 3Q26 pro forma +HSD revenue • +LSD Reproductive Health with +MSD growth ex -China • Si
Slide 8: 2026 Pro Forma Financial Guidance
2026 Pro Forma* Financial Guidance REVENUE ~$2.86B Total : ~6% Organic: ~5% FX: +0.5%, M&A: +0.75 % ADJUSTED OP. MARGIN ~28.8% ADJUSTED EPS $5.40 - $5.45 Adj. net interest expense, other: ~$88M Adj. tax rate: ~18 % Average diluted share count: ~112M *Pro Forma excludes the impact of the China Immuno